|Bid||5.19 x 100|
|Ask||8.94 x 1000|
|Day's Range||6.57 - 6.67|
|52 Week Range||4.84 - 11.72|
|PE Ratio (TTM)||68.14|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||13.50|
NEW YORK, July 26, 2017-- Progenics Pharmaceuticals, Inc.,, an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Progenics Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to PGNX-US. Comparing the performance and risk of Progenics Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Cantor Fitzgerald analyst Mara Goldstein initiated coverage on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX ) with an Overweight rating and $15 price target. The stock jumped 2.4 percent Wednesday to ...